BACKGROUND/AIMS: Serum YKL-40 has been linked to several human cancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies. METHODS: Archived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease. RESULTS: The median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259 ng/mL in the HCC group and 80 ng/mL in the CCA group (p<0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p<0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis. CONCLUSIONS: The serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined.
BACKGROUND/AIMS: Serum YKL-40 has been linked to several humancancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies. METHODS: Archived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease. RESULTS: The median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259 ng/mL in the HCC group and 80 ng/mL in the CCA group (p<0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p<0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis. CONCLUSIONS: The serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined.
Entities:
Keywords:
Cholangiocarcinoma; End stage liver disease; Hepatocellular carcinoma; Model for end-stage liver disease; YKL-40
Authors: Klaus Brasso; Ib Jarle Christensen; Julia S Johansen; Børge Teisner; Patrick Garnero; Paul A Price; Peter Iversen Journal: Prostate Date: 2006-04-01 Impact factor: 4.104
Authors: S H Lau; J S T Sham; D Xie; C-H Tzang; D Tang; N Ma; L Hu; Y Wang; J-M Wen; G Xiao; W-M Zhang; G K K Lau; M Yang; X-Y Guan Journal: Oncogene Date: 2006-02-23 Impact factor: 9.867
Authors: Henrik Schmidt; Julia Sidenius Johansen; Julie Gehl; Poul F Geertsen; Kirsten Fode; Hans von der Maase Journal: Cancer Date: 2006-03-01 Impact factor: 6.860
Authors: Geoffrey L Chupp; Chun Geun Lee; Nizar Jarjour; Yun Michael Shim; Carole T Holm; Susan He; James D Dziura; Jennifer Reed; Anthony J Coyle; Peter Kiener; Mark Cullen; Martine Grandsaigne; Marie-Christine Dombret; Michel Aubier; Marina Pretolani; Jack A Elias Journal: N Engl J Med Date: 2007-11-15 Impact factor: 91.245
Authors: Preeti Mehta; Robert Ploutz-Snyder; Jyotirmoy Nandi; Sekou R Rawlins; Schuyler O Sanderson; Robert A Levine Journal: Am J Gastroenterol Date: 2008-03-25 Impact factor: 10.864
Authors: Camilla Noelle Rathcke; Frederik Persson; Lise Tarnow; Peter Rossing; Henrik Vestergaard Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Anders R Nielsen; Christian Erikstrup; Julia S Johansen; Christian P Fischer; Peter Plomgaard; Rikke Krogh-Madsen; Sarah Taudorf; Birgitte Lindegaard; Bente K Pedersen Journal: Diabetes Date: 2008-07-23 Impact factor: 9.461
Authors: Nicolai A Schultz; Ib J Christensen; Jens Werner; Nathalia Giese; Benny V Jensen; Ole Larsen; Jon K Bjerregaard; Per Pfeiffer; Dan Calatayud; Svend E Nielsen; Mette K Yilmaz; Niels H Holländer; Morten Wøjdemann; Stig E Bojesen; Kaspar R Nielsen; Julia S Johansen Journal: PLoS One Date: 2013-06-26 Impact factor: 3.240